KAZUNORI MARUYAMA

Kazunori Maruyama stands at the forefront of healthcare innovation as the President of Astellas Venture Management (AVM). AVM operates as the dedicated corporate venture capital fund of Astellas Pharma Inc., a global pharmaceutical company committed to turning innovative science into value for patients. Under Maruyama's leadership, AVM plays a crucial role in identifying, nurturing, and investing in promising early-stage companies that are developing transformative technologies and therapies in the life sciences sector.

His primary responsibility involves guiding AVM's investment strategy, ensuring alignment with Astellas Pharma's long-term strategic goals and therapeutic focus areas. This includes a keen interest in novel drug discovery platforms, gene and cell therapies, regenerative medicine, digital health solutions, and advanced medical devices. Maruyama's vision helps Astellas Pharma expand its external innovation pipeline, fostering collaborations that can lead to significant breakthroughs in patient care. The fund actively seeks out companies with disruptive potential, aiming to complement Astellas' internal research and development efforts and accelerate the delivery of new medicines to market.

Kazunori Maruyama's career background is deeply rooted in the pharmaceutical industry, reflecting a profound understanding of drug development, corporate strategy, and business development within the life sciences. Prior to assuming the presidency at Astellas Venture Management, he held various leadership positions within Astellas Pharma. These roles likely encompassed strategic planning, alliance management, and corporate development, where he was instrumental in forging key partnerships and evaluating strategic investment opportunities. His extensive experience provides him with a unique perspective on the challenges and opportunities within the biotech and pharmaceutical landscape, enabling him to make informed investment decisions that drive both financial returns and strategic value for Astellas.

While specific individual investments are often attributed to the fund rather than a single person, under Maruyama's guidance, Astellas Venture Management has made strategic investments in a diverse portfolio of innovative companies. These investments typically target firms developing cutting-edge solutions in oncology, immunology, neuroscience, and other areas of high unmet medical need. For instance, AVM has invested in companies leveraging CRISPR technology for gene editing, developing advanced immunotherapies, or pioneering new approaches to treat neurodegenerative diseases. These strategic investments underscore Maruyama's commitment to advancing medical science and bringing forward the next generation of healthcare solutions.

Kazunori Maruyama's leadership at Astellas Venture Management is critical for Astellas Pharma's future growth, ensuring the company remains at the cutting edge of scientific discovery and innovation. His strategic acumen and deep industry knowledge make him a key figure in the corporate venture capital landscape, particularly within the highly specialized and impactful field of life sciences investment.